Sunovion's Latuda wins FDA nod for bipolar depression

07/2/2013 | Pharmaceutical Business Review Online

Sunovion Pharmaceuticals obtained the FDA's approval to market Latuda, or lurasidone, as a monotherapy and in combination with either lithium or valproate in adults with bipolar depression. The approval was based on favorable data from two double-blind studies.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL